Allogene Therapeutics (ALLO) Current Deferred Revenue (2020 - 2024)

Allogene Therapeutics has disclosed Current Deferred Revenue across 5 years of filings, most recently posting $86000.0 for Q1 2024.

• Current Deferred Revenue for Q1 2024 came in at $86000.0, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2024 was $86000.0 (changed 0.0% YoY), and the FY2023 annual result was $86000.0, down 9.47% from the prior year.
• Current Deferred Revenue came in at $86000.0 for Q1 2024 at Allogene Therapeutics, roughly flat from $86000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $39.0 million in Q4 2020 to a low of $86000.0 in Q1 2023.
• The 5-year median for Current Deferred Revenue is $101500.0 (2022), against an average of $2.9 million.
• Across the five-year window, Current Deferred Revenue slumped 99.6% in 2021 and changed 0.0% in 2024, its largest moves.
• Allogene Therapeutics' Current Deferred Revenue stood at $39.0 million in 2020, then slumped by 99.6% to $156000.0 in 2021, then tumbled by 39.1% to $95000.0 in 2022, then retreated by 9.47% to $86000.0 in 2023, then changed by 0.0% to $86000.0 in 2024.
• The last three Current Deferred Revenue figures came in at $86000.0 (Q1 2024), $86000.0 (Q4 2023), and $86000.0 (Q3 2023), per Business Quant data.